pioglitazone has been researched along with Cognition Disorders in 17 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Specifically, IRIS will test the effectiveness of pioglitazone, an insulin-sensitizing drug of the thiazolidinedione class, for reducing the risk for stroke and myocardial infarction (MI) among insulin resistant, nondiabetic patients with a recent ischemic stroke or TIA." | 9.19 | Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: rationale and design of the Insulin Resistance Intervention after Stroke Trial. ( Brass, LM; Carolei, A; Conwit, R; Ford, GA; Furie, KL; Gorman, M; Guarino, PD; Inzucchi, SE; Kernan, WN; Lovejoy, AM; Parsons, MW; Peduzzi, PN; Ringleb, PA; Schwartz, GG; Spence, JD; Tanne, D; Viscoli, CM; Young, LH, 2014) |
| "To test the effects of the PPAR-γ agonist pioglitazone on cognition, regional cerebral blood flow (rCBF), and plasma levels of Aβ40 and Aβ42, we conducted a 6-month, randomized, open-controlled trial in patients with mild Alzheimer disease (AD) accompanied with type II diabetes mellitus." | 9.15 | Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease. ( Hanyu, H; Hirao, K; Iwamoto, T; Kanetaka, H; Sakurai, H; Sato, T, 2011) |
| " Specifically, IRIS will test the effectiveness of pioglitazone, an insulin-sensitizing drug of the thiazolidinedione class, for reducing the risk for stroke and myocardial infarction (MI) among insulin resistant, nondiabetic patients with a recent ischemic stroke or TIA." | 5.19 | Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: rationale and design of the Insulin Resistance Intervention after Stroke Trial. ( Brass, LM; Carolei, A; Conwit, R; Ford, GA; Furie, KL; Gorman, M; Guarino, PD; Inzucchi, SE; Kernan, WN; Lovejoy, AM; Parsons, MW; Peduzzi, PN; Ringleb, PA; Schwartz, GG; Spence, JD; Tanne, D; Viscoli, CM; Young, LH, 2014) |
| "To test the effects of the PPAR-γ agonist pioglitazone on cognition, regional cerebral blood flow (rCBF), and plasma levels of Aβ40 and Aβ42, we conducted a 6-month, randomized, open-controlled trial in patients with mild Alzheimer disease (AD) accompanied with type II diabetes mellitus." | 5.15 | Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease. ( Hanyu, H; Hirao, K; Iwamoto, T; Kanetaka, H; Sakurai, H; Sato, T, 2011) |
| "Pioglitazone did not increase weight or produce any other significant side-effects." | 2.78 | Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: a randomized double-blind study. ( Bark, N; Davis, JM; Dwivedi, S; Hu, Q; Jin, H; Li, C; Lohr, J; Mortiere, C; Shekhar, A; Smith, RC, 2013) |
| "Similar insulin resistance is found in type 2 diabetes and is currently treated with insulin sensitizers (IS)." | 2.61 | A systematic literature review of the effect of insulin sensitizers on the cognitive symptoms of Alzheimer's Disease in transgenic mice. ( Craig, A; Issberner, J; Parvez, F, 2019) |
| " The current study was carried out to investigate the effects of chronic administration of pioglitazone, a PPAR-γ agonist, on cognitive impairment in an animal model of Alzheimer's disease induced by β-amyloid." | 1.40 | Role of nuclear receptor on regulation of BDNF and neuroinflammation in hippocampus of β-amyloid animal model of Alzheimer's disease. ( Kumar, A; Prakash, A, 2014) |
| "Treatment with Pioglitazone prevented the increase in the number of activated microglia and no difference was observed between sham and Pioglitazone-treated animals." | 1.37 | Pioglitazone attenuates mitochondrial dysfunction, cognitive impairment, cortical tissue loss, and inflammation following traumatic brain injury. ( Bing, G; Gao, J; Liu, M; Pauly, JR; Readnower, R; Sauerbeck, A; Sullivan, PG, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (11.76) | 29.6817 |
| 2010's | 15 (88.24) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Craig, A | 1 |
| Parvez, F | 1 |
| Issberner, J | 1 |
| Prakash, A | 2 |
| Kumar, A | 2 |
| Aghaei, I | 1 |
| Shabani, M | 1 |
| Doustar, N | 1 |
| Nazeri, M | 1 |
| Dehpour, A | 1 |
| Kummer, MP | 1 |
| Schwarzenberger, R | 1 |
| Sayah-Jeanne, S | 1 |
| Dubernet, M | 1 |
| Walczak, R | 1 |
| Hum, DW | 1 |
| Schwartz, S | 1 |
| Axt, D | 1 |
| Heneka, MT | 1 |
| Viscoli, CM | 1 |
| Brass, LM | 1 |
| Carolei, A | 1 |
| Conwit, R | 1 |
| Ford, GA | 1 |
| Furie, KL | 1 |
| Gorman, M | 1 |
| Guarino, PD | 1 |
| Inzucchi, SE | 1 |
| Lovejoy, AM | 1 |
| Parsons, MW | 1 |
| Peduzzi, PN | 1 |
| Ringleb, PA | 1 |
| Schwartz, GG | 1 |
| Spence, JD | 1 |
| Tanne, D | 1 |
| Young, LH | 1 |
| Kernan, WN | 1 |
| Lan, LF | 1 |
| Zheng, L | 1 |
| Yang, X | 1 |
| Ji, XT | 1 |
| Fan, YH | 1 |
| Zeng, JS | 1 |
| Skerrett, R | 1 |
| Pellegrino, MP | 1 |
| Casali, BT | 1 |
| Taraboanta, L | 1 |
| Landreth, GE | 1 |
| Jain, S | 1 |
| Sharma, BM | 1 |
| Sharma, B | 1 |
| Hanyu, H | 2 |
| Sato, T | 2 |
| Kiuchi, A | 1 |
| Sakurai, H | 2 |
| Iwamoto, T | 2 |
| Hirao, K | 1 |
| Kanetaka, H | 1 |
| Baraka, A | 1 |
| ElGhotny, S | 1 |
| Sauerbeck, A | 1 |
| Gao, J | 1 |
| Readnower, R | 1 |
| Liu, M | 1 |
| Pauly, JR | 1 |
| Bing, G | 1 |
| Sullivan, PG | 1 |
| Semple, BD | 1 |
| Noble-Haeusslein, LJ | 1 |
| Jiang, LY | 1 |
| Tang, SS | 1 |
| Wang, XY | 1 |
| Liu, LP | 1 |
| Long, Y | 1 |
| Hu, M | 1 |
| Liao, MX | 1 |
| Ding, QL | 1 |
| Hu, W | 1 |
| Li, JC | 1 |
| Hong, H | 1 |
| Smith, RC | 1 |
| Jin, H | 1 |
| Li, C | 1 |
| Bark, N | 1 |
| Shekhar, A | 1 |
| Dwivedi, S | 1 |
| Mortiere, C | 1 |
| Lohr, J | 1 |
| Hu, Q | 1 |
| Davis, JM | 1 |
| Zhao, W | 1 |
| Payne, V | 1 |
| Tommasi, E | 1 |
| Diz, DI | 1 |
| Hsu, FC | 1 |
| Robbins, ME | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Insulin Resistance Intervention After Stroke (IRIS) Trial[NCT00091949] | Phase 3 | 3,876 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia Treated With Antipsychotic Medication And Potential Effects on Cognitive Function[NCT00231894] | Phase 4 | 56 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Fatal or non-fatal acute myocardial infarction or unstable angina (NCT00091949)
Timeframe: 5 years
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 206 |
| Placebo | 249 |
(NCT00091949)
Timeframe: 5 years
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 136 |
| Placebo | 146 |
(NCT00091949)
Timeframe: 5 years
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 206 |
| Placebo | 249 |
Change in modified mental status examination (3MS) score from baseline to exit. Theoretical range of 3MS scores is 0-100. Baseline scores ranged from 22-100. (NCT00091949)
Timeframe: Annual measures from baseline to exit (up to 5 years)
| Intervention | units on a scale (Mean) |
|---|---|
| Pioglitazone | 0.27 |
| Placebo | 0.29 |
(NCT00091949)
Timeframe: 5 years
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 73 |
| Placebo | 149 |
(NCT00091949)
Timeframe: 5 years
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 127 |
| Placebo | 154 |
(NCT00091949)
Timeframe: Up to 5 years
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 175 |
| Placebo | 228 |
difference between 2 hr glucose for GTT test at baseline vs after 3 months of drug treatment (NCT00231894)
Timeframe: between baseline and 3 months of study drug treatment
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone | -6.82 |
| Placebo | -40.72 |
difference between 2 hr glucose for GTT test at baseline vs after 3 months of drug treatment (NCT00231894)
Timeframe: between baseline and 3 months of study drug treatment
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone | -24.19 |
| Placebo | 15.19 |
(NCT00231894)
Timeframe: pretreatment and during 3 months of drug treatment
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone | -13.33 |
| Placebo | -11.5 |
(NCT00231894)
Timeframe: pretreatment and during 3 months of drug treatment
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone | 0.02 |
| Placebo | 24.20 |
(NCT00231894)
Timeframe: pretreatment and during 3 months of drug treatment
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone | 6.52 |
| Placebo | 7.72 |
serum high density lipoprotein (HDL) (NCT00231894)
Timeframe: pre-treatment and during 3 months of treatment
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Piogltiazone | 4.62 |
| Placebo | -2.59 |
(NCT00231894)
Timeframe: pre-treatment and during 3 months of treatment
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone | -49.65 |
| Placebo | 30.99 |
(NCT00231894)
Timeframe: pretreatment and during 3 months of drug treatment
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone | 32.56 |
| Placebo | -79.12 |
The scale is Repeatable Battery for the Assessment to Neuropsychological Status (RBANS). This scale measure cognitive function in patients with schizophrenia. Range for list learning sub-score is 0 to 20 . Higher values indicate better performance. For change score (3 months -baseline) positive values indicate improved performance for this cognitive function and negative values indicate poorer performance on this cognitive function. (NCT00231894)
Timeframe: pre-treatment and 3 months of treatment
| Intervention | Units on RBANS scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 0.27 |
| Placebo | -1.11 |
1 review available for pioglitazone and Cognition Disorders
| Article | Year |
|---|---|
A systematic literature review of the effect of insulin sensitizers on the cognitive symptoms of Alzheimer's Disease in transgenic mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Brain; Cognition; | 2019 |
4 trials available for pioglitazone and Cognition Disorders
| Article | Year |
|---|---|
Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: rationale and design of the Insulin Resistance Intervention after Stroke Trial.
Topics: Adult; Cognition Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; H | 2014 |
Pioglitazone improved cognition in a pilot study on patients with Alzheimer's disease and mild cognitive impairment with diabetes mellitus.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognition Disorders; Diabetes Mellitus; Female; Humans; | 2009 |
Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognition Disorders; Diabetes Mellitus, Type 2; Female; | 2011 |
Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: a randomized double-blind study.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Antisocial Personality Disorder; Case-Control Stu | 2013 |
12 other studies available for pioglitazone and Cognition Disorders
| Article | Year |
|---|---|
Pioglitazone alleviates the mitochondrial apoptotic pathway and mito-oxidative damage in the d-galactose-induced mouse model.
Topics: Acetylcholinesterase; Aging; Animals; Antioxidants; Apoptosis; Behavior, Animal; Brain; Caspase 3; C | 2013 |
Role of nuclear receptor on regulation of BDNF and neuroinflammation in hippocampus of β-amyloid animal model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain-Derived Neurotrophic Factor; Cognition Diso | 2014 |
Peroxisome proliferator-activated receptor-γ activation attenuates motor and cognition impairments induced by bile duct ligation in a rat model of hepatic cirrhosis.
Topics: Animals; Avoidance Learning; Bile Duct Diseases; Bile Ducts; Cognition Disorders; Hypoglycemic Agent | 2014 |
Pan-PPAR modulation effectively protects APP/PS1 mice from amyloid deposition and cognitive deficits.
Topics: Amyloid beta-Protein Precursor; Animals; Chlorocebus aethiops; Cognition Disorders; COS Cells; Femal | 2015 |
Peroxisome proliferator-activated receptor-γ agonist pioglitazone ameliorates white matter lesion and cognitive impairment in hypertensive rats.
Topics: Animals; Blood Pressure; Brain; Cognition Disorders; Disease Models, Animal; Male; Maze Learning; Ne | 2015 |
Combined Liver X Receptor/Peroxisome Proliferator-activated Receptor γ Agonist Treatment Reduces Amyloid β Levels and Improves Behavior in Amyloid Precursor Protein/Presenilin 1 Mice.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Apolipoproteins E; Behavior, Animal; Ben | 2015 |
Calcium Channel Blockade and Peroxisome Proliferator Activated Receptor γ Agonism Diminish Cognitive Loss and Preserve Endothelial Function During Diabetes Mellitus.
Topics: Animals; Attention; Blood-Brain Barrier; Brain; Calcium Channel Blockers; Calcium Channels; Capillar | 2016 |
Study of the effect of inhibiting galanin in Alzheimer's disease induced in rats.
Topics: Administration, Oral; Alzheimer Disease; Amyloid beta-Peptides; Animals; Avoidance Learning; Brain; | 2010 |
Pioglitazone attenuates mitochondrial dysfunction, cognitive impairment, cortical tissue loss, and inflammation following traumatic brain injury.
Topics: Analysis of Variance; Animals; Brain Injuries; CD11b Antigen; Cerebral Cortex; Cognition Disorders; | 2011 |
Broad-spectrum neuroprotection against traumatic brain injury by agonism of peroxisome proliferator-activated receptors.
Topics: Animals; Brain Injuries; Cerebral Cortex; Cognition Disorders; Disease Models, Animal; Encephalitis; | 2011 |
PPARγ agonist pioglitazone reverses memory impairment and biochemical changes in a mouse model of type 2 diabetes mellitus.
Topics: Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Aspartic Acid Endopeptidases; | 2012 |
Administration of the peroxisomal proliferator-activated receptor gamma agonist pioglitazone during fractionated brain irradiation prevents radiation-induced cognitive impairment.
Topics: Analysis of Variance; Animals; Body Weight; Brain; Cognition; Cognition Disorders; Cranial Irradiati | 2007 |